Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Midlife sensory and motor functions improve prediction of blood-based measures of neurodegeneration and Alzheimer's disease in late middle-age.
Paulsen AJ, Pinto AA, Schubert CR, Chappell RJ, Chen Y, Engelman CD, Ferrucci L, Hancock LM, Johnson SC, Merten N. Paulsen AJ, et al. Among authors: hancock lm. Alzheimers Dement (Amst). 2024 Mar 11;16(1):e12564. doi: 10.1002/dad2.12564. eCollection 2024 Jan-Mar. Alzheimers Dement (Amst). 2024. PMID: 38476637 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 39750602
Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
Covey TJ, Golan D, Sergott R, Wilken J, Zarif M, Bumstead B, Buhse M, Kaczmarek O, Doniger GM, Penner IK, Hancock LM, Bogaardt H, Barrera MA, Morrow SA, Galetta S, Gudesblatt M. Covey TJ, et al. Among authors: hancock lm. J Neurol. 2024 Feb;271(2):658-673. doi: 10.1007/s00415-023-12075-5. Epub 2023 Dec 13. J Neurol. 2024. PMID: 38091086
Cognitive impairment, fatigue and depression in multiple sclerosis: Is there a difference between benign and non-benign MS?
Bogaardt H, Golan D, Barrera MA, Attrill S, Kaczmarek O, Zarif M, Bumstead B, Buhse M, Wilken J, Doniger GM, Hancock LM, Penner IK, Halper J, Morrow SA, Covey TJ, Gudesblatt M. Bogaardt H, et al. Among authors: hancock lm. Mult Scler Relat Disord. 2023 May;73:104630. doi: 10.1016/j.msard.2023.104630. Epub 2023 Mar 21. Mult Scler Relat Disord. 2023. PMID: 36965219 Free article.
De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate.
Gudesblatt M, Bumstead B, Buhse M, Zarif M, Morrow SA, Nicholas JA, Hancock LM, Wilken J, Weller J, Scott N, Gocke A, Lewin JB, Kaczmarek O, Mendoza JP, Golan D. Gudesblatt M, et al. Among authors: hancock lm. Adv Ther. 2024 Aug;41(8):3059-3075. doi: 10.1007/s12325-024-02902-0. Epub 2024 Jun 11. Adv Ther. 2024. PMID: 38861218 Free PMC article.
35 results